162 related articles for article (PubMed ID: 27666284)
1. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
[TBL] [Abstract][Full Text] [Related]
2. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
[TBL] [Abstract][Full Text] [Related]
3. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
[TBL] [Abstract][Full Text] [Related]
4. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
6. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
8. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
9. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
10. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
Reagan PM; Friedberg JW
Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
[TBL] [Abstract][Full Text] [Related]
12. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
13. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
14. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection.
Attarbaschi A; Beishuizen A; Mann G; Rosolen A; Mori T; Uyttebroeck A; Niggli F; Csoka M; Krenova Z; Mellgren K; Kabickova E; Chiang AK; Reiter A; Williams D; Burkhardt B;
Ann Hematol; 2013 Nov; 92(11):1537-41. PubMed ID: 23665980
[TBL] [Abstract][Full Text] [Related]
15. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
Yuda S; Miyagi Maeshima A; Taniguchi H; Ito Y; Hatta S; Suzuki T; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Eur J Haematol; 2021 Jul; 107(1):157-165. PubMed ID: 33905571
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Kahl B
Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.
El-Galaly TC; Bilgrau AE; de Nully Brown P; Mylam KJ; Ahmad SA; Pedersen LM; Gang AO; Bentzen HH; Juul MB; Bergmann OJ; Pedersen RS; Nielsen BJ; Johnsen HE; Dybkaer K; Bøgsted M; Hutchings M
Br J Haematol; 2015 May; 169(3):435-44. PubMed ID: 25709094
[TBL] [Abstract][Full Text] [Related]
19. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
[TBL] [Abstract][Full Text] [Related]
20. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
